Navigation Links
AMDL Inc.'s JJB Plant Receives Production Approval From Chinese State Food and Drug Administration (SFDA)
Date:5/8/2009

TUSTIN, Calif., May 8 /PRNewswire-FirstCall/ -- AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today its JJB wholly foreign-owned subsidiary located in Shangrao, Jiangxi Province, China has received approval from the Chinese State Food and Drug Administration (SFDA) to re-initiate product production on its small injectable manufacturing line which is specifically used to produce the Goodnak(R) anti-aging injectable product and other small volume parenteral solutions.

The SFDA requires all China-based companies engaged in the manufacture of pharmaceutical products to have "Good Manufacturing Practices" (GMP) certification. In Q108, JJB's GMP certification expired and the Company initiated $1.5 million in plant renovations to bring the facility and its operations into compliance with the SFDA. With today's announcement, JJB has reopened the Jiangxi-based plant and resumed operations for its small injectable manufacturing line.

According to Mr. Douglas MacLellan, Chairman and CEO of AMDL, "Based on the pending renewal of our GMP-certification for the JJB plant we anticipated a temporary cease in operations at JJB and planned accordingly by successfully amounting adequate product supply to meet distributor demand through SFDA approval. The manufacturing lines at this facility have resumed operations and we remain on track with our quarterly and fiscal year business and financial projections."

For additional information on AMDL, its FY09 financial forecast, portfolio of international health and beauty products, and 2009 business strategy, visit the Company's website at www.amdl.com or contact AMDL Investor Relations at kszarkowitz@amdl.com .

About AMDL:

Headquartered in Tustin, CA with operations in China, AMDL Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 500 people in the US and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

    AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    kszarkowitz@amdl.com
    (Tel :) 206.310.5323


'/>"/>
SOURCE AMDL Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Preclinical study suggests organ-transplant drug may aid in lupus fight
2. Study provides hope that some transplant patients could live free of antirejection drugs
3. Study provides hope that some transplant patients could live free of anti-rejection drugs
4. Advanced Age No Bar to Liver Transplant
5. Nanowire coating for bone implants, stents
6. Circulating fats kill transplanted pancreas cells, study shows
7. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
8. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
9. Implantable device designed to detect, stop seizures under study at MCG
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. Bone-growing nanomaterial could improve orthopaedic implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... In today’s world, homeowners ... on the market, it is easy to start feeling frustrated and confused. To ... a complimentary security consultation. , Home Security Hardware Choices, There are innumerable choices ...
(Date:2/22/2017)... ... 22, 2017 , ... Apptricity® Corporation, a leading global provider ... today announced that Keppel Corporation has selected Apptricity Travel and Expense Management integrated ... are excited to announce the partnership between Keppel and Apptricity for our Global ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... Nation Regional Medical Clinic in Durant, Oklahoma, on Feb. 21. , The celebration ... tours for community members, clinic employees, the construction team and tribal leadership. ...
(Date:2/21/2017)... ... February 21, 2017 , ... Doctors on Liens has announced the ... Dr. Kendell Mendonca , to its growing network of doctors in Central and Northern ... from car accidents such as whiplash, back pain, neck pain, hip and knee pain, ...
(Date:2/21/2017)... , ... February 21, 2017 , ... Ray Insurance Agencies, ... in and around Tarrant County, is embarking on a six month charity event aimed ... treatments for cancer. , Cancer is one of the deadliest diseases in America; more ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, ... new research agreements and the appointment of Professor ... , MD, PhD, FRCP, as scientific advisors. The aim ... drug compounds in development for the treatment of NASH ... new collaboration with Philippe Gallay , the research ...
(Date:2/21/2017)... Feb. 21, 2017 Mass Spectrometer Market: ... http://www.reportlinker.com/p04711309-summary/view-report.html This report on mass ... future prospects of the market globally. The stakeholders ... in the manufacture and commercialization of various mass ... entrants planning to enter this market. This report ...
(Date:2/21/2017)...  IBM (NYSE: IBM ) Research has today announced ... of the eye,s retina. The Melbourne ... to recognize abnormalities in retina images, which could in the ... identification of patients who may be at risk of eye ... in the developed world. The research began ...
Breaking Medicine Technology: